FILING ANALYSIS · FRIDAY, NOVEMBER 13
Benitec Biopharma Inc. BNTC — 8-K: Results of Operations and Financial Condition
neutral
Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, and presented positive interim clinical results from the ongoing BB-301 Phase 1b/2a study, but the update lacks a quantified surprise to drive a significant price move
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →